Organogenesis Holdings Inc. (ORGO) shareholders
Close on Nov 17, 2026Market cap $104.43MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Thompson Dean Joint filing with David Burgstahler (17.60%), Avista Capital Partners VI GP, L.P. (16.70%) and 3 more | 28,680,359 | 18.00% | 13D (active) | Nov 12, 2024 |
| Alan A. Ades Joint filing with Albert Erani (14.10%), Glenn H. Nussdorf (9.40%) and 6 more | 22,319,836 | 17.60% | 13D (active) amendment | Jun 24, 2025 |
| Soleus Capital Group, LLC Joint filing with Soleus Capital Master Fund, L.P. (9.90%), Soleus Capital, LLC (9.90%) and 3 more | 12,484,876 | 9.90% | 13G (passive) amendment | Dec 31, 2024 |
| Glenn H. Nussdorf Joint filing with GN 2016 Organo 10-Year GRAT u/a/d September 30, 2016 (6.20%) | 12,248,560 | 9.70% | 13D (active) amendment | May 14, 2025 |
| Morgan Stanley Joint filing with Morgan Stanley & Co. LLC (8.70%) | 11,505,331 | 8.70% | 13G (passive) | Dec 31, 2023 |
| Soleus Capital Management, L.P. Joint filing with Soleus Capital Master Fund, L.P. (7.90%), Soleus Capital, LLC (7.90%) and 3 more | 9,985,951 | 7.90% | 13G (passive) amendment | Dec 31, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ORGO | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Morgan Stanley | 11,721,609 | 9.11% | $28.48M | +104,814 | 0.00% |
| Soleus Capital Management, L.P. | 10,140,951 | 7.88% | $24.64M | +55,000 | 0.85% |
| BlackRock, Inc. | 7,249,528 | 5.63% | $17.62M | +2,349,777 | 0.00% |
| Assenagon Asset Management S.A. | 3,935,904 | 3.06% | $9.56M | +1,967,952 | 0.01% |
| Dimensional Fund Advisors LP | 3,050,297 | 2.37% | $7.41M | +159,291 | 0.00% |
| Aqr Capital Management LLC | 3,011,753 | 2.34% | $7.32M | +2,130,036 | 0.00% |
| Vanguard Capital Management LLC | 2,905,919 | 2.26% | $7.06M | +5,103 | 0.00% |
| D. E. Shaw & Co., Inc. | 2,888,313 | 2.24% | $7.02M | +590,339 | 0.00% |
| Geode Capital Management, LLC | 1,935,554 | 1.50% | $4.70M | +151,590 | 0.00% |
| Deutsche Bank AG\ | 1,706,186 | 1.33% | $4.15M | +505 | 0.00% |
| Vanguard Portfolio Management LLC | 1,607,729 | 1.25% | $3.91M | +158,637 | 0.00% |
| Acadian Asset Management LLC | 1,545,086 | 1.20% | $3.75M | −31,559 | 0.00% |
| State Street Corp | 1,519,955 | 1.18% | $3.69M | −5,153 | 0.00% |
| Renaissance Technologies LLC | 1,017,113 | 0.79% | $2.47M | −51,425 | 0.00% |
| Charles Schwab Investment Management Inc | 905,024 | 0.70% | $2.20M | +25,192 | 0.00% |
| Goldman Sachs Group Inc | 887,399 | 0.69% | $2.16M | +367,049 | 0.00% |
| Citadel Advisors LLC | 867,929 | 0.67% | $2.11M | +323,694 | 0.00% |
| Flax Pond Capital, LLC | 842,682 | 0.65% | $2.02M | +422,591 | 0.75% |
| SG Americas Securities, LLC | 772,737 | 0.60% | $1.88M | −18,029 | 0.00% |
| Jacobs Levy Equity Management, Inc | 692,197 | 0.54% | $1.68M | New | 0.01% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 135 | 68M | 53.2% | 31 / 55 | 32 / 15 | 13M | 6M |
| Q1 2026 | 121 | 62M | 48.0% | 16 / 35 | 48 / 40 | 9M | 11M |
| Q4 2025 | 147 | 69M | 54.0% | 35 / 42 | 47 / 9 | 9M | 8M |
| Q3 2025 | 121 | 69M | 53.3% | 22 / 31 | 44 / 16 | 4M | 4M |
| Q2 2025 | 115 | 69M | 54.0% | 22 / 30 | 49 / 41 | 14M | 9M |
| Q1 2025 | 136 | 65M | 50.5% | 28 / 44 | 47 / 11 | 8M | 6M |
| Q4 2024 | 120 | 63M | 48.7% | 22 / 41 | 35 / 13 | 5M | 6M |
| Q3 2024 | 112 | 64M | 49.9% | 14 / 40 | 39 / 15 | 11M | 5M |
| Q2 2024 | 116 | 63M | 49.1% | 19 / 51 | 31 / 27 | 9M | 26M |
| Q1 2024 | 124 | 80M | 62.4% | 28 / 37 | 45 / 12 | 14M | 5M |
| Q4 2023 | 108 | 72M | 55.7% | 21 / 33 | 37 / 16 | 27M | 7M |
| Q3 2023 | 104 | 53M | 40.8% | 14 / 35 | 37 / 22 | 10M | 9M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
147 funds held ORGO in Q2 2026, 55% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of ORGO | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1,991,446 | 1.55% | $4.84M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,804,253 | 1.40% | $4.38M | 0.01% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 842,139 | 0.65% | $2.05M | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 754,323 | 0.59% | $1.79M | 0.01% | Jul 31, 2026 |
| iShares Russell 2000 Value ETF | 629,191 | 0.49% | $1.53M | 0.01% | Jun 30, 2026 |
| Vanguard Explorer Fund | 492,497 | 0.38% | $1.17M | 0.01% | Jul 31, 2026 |
| Fidelity Extended Market Index Fund | 396,236 | 0.31% | $1.02M | 0.00% | May 31, 2026 |
| U.S. Targeted Value Portfolio | 356,422 | 0.28% | $844.72K | 0.01% | Jul 31, 2026 |
| Vanguard Russell 2000 Index Fund | 352,129 | 0.27% | $904.97K | 0.01% | May 31, 2026 |
| Schwab U.S. Small-Cap ETF | 350,724 | 0.27% | $901.36K | 0.00% | May 31, 2026 |
| Schwab Small-Cap Equity Fund | 341,648 | 0.27% | $809.71K | 0.12% | Jul 31, 2026 |
| Vanguard Strategic Equity Fund | 334,062 | 0.26% | $811.77K | 0.01% | Jun 30, 2026 |
| Dimensional U.S. Small Cap ETF | 295,905 | 0.23% | $701.29K | 0.00% | Jul 31, 2026 |
| U.S. Small Cap Value Portfolio | 284,690 | 0.22% | $674.72K | 0.00% | Jul 31, 2026 |
| Dimensional US Small Cap Value ETF | 267,878 | 0.21% | $634.87K | 0.01% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Gary S. Gillheeney | President and CEO, Director | 4,323,398 | 3.36% | Mar 3, 2026 |
| Brian Grow | Chief Commercial Officer | 900,682 | 0.70% | Apr 24, 2026 |
| Robert Cavorsi | Vice President, Strategy | 275,524 | 0.21% | Mar 3, 2026 |
| Patrick Bilbo | Chief Operating Officer | 1,128,312 | 0.88% | Mar 3, 2026 |
| Antonio S. Montecalvo | Vice President, Health Policy | 230,016 | 0.18% | Mar 3, 2026 |
| David Francisco | Chief Financial Officer | 745,999 | 0.58% | Mar 3, 2026 |
| Lori Freedman | Chief Admin. and Legal Officer | 1,023,643 | 0.80% | Mar 3, 2026 |
| Patrick McGuire | Chief Accounting Officer | 16,965 | 0.01% | Feb 27, 2026 |
| Michael Joseph Driscoll | Director | 225,707 | 0.18% | Mar 11, 2026 |
| Arthur S. Leibowitz | Director | 291,014 | 0.23% | Mar 11, 2026 |
| Jon L. Giacomin | Director | 241,026 | 0.19% | Feb 20, 2026 |
| Gilberto Quintero | Director | 239,073 | 0.19% | Feb 20, 2026 |
| Prathyusha Duraibabu | Director | 247,047 | 0.19% | Feb 20, 2026 |
| Michele Ilene Korfin | Director | 239,073 | 0.19% | Feb 20, 2026 |
| Garrett Lustig | Director | 125,742 | 0.10% | Feb 20, 2026 |
| Glenn H. Nussdorf | Director | 11,748,560 | 9.13% | Dec 18, 2025 |
| Alan A. Ades | Director, 10% owner | 102,170,806 | 79.40% | Jan 13, 2025 |
| Erani 2012 Issue Trust dated 12/20/12 Dennis | 10% owner | 59,007,134 | 45.86% | Jan 13, 2025 |
| Investors LLC Organo | 10% owner | 118,896,054 | 92.40% | Jan 13, 2025 |
| Starr Wisdom | 10% owner | 195,109,087 | 151.63% | Jan 13, 2025 |
| GN 2016 Organo 10-Year GRAT u/a/d September 30, 2016 | 10% owner | 59,007,134 | 45.86% | Jan 13, 2025 |
| Erani Family Trust dated 12/29/2012 Albert | 10% owner | 102,170,804 | 79.40% | Jan 13, 2025 |
| Ades 2014 GRAT Alan | 10% owner | 118,896,054 | 92.40% | Jan 13, 2025 |
| Dennis Erani | 10% owner | 118,896,054 | 92.40% | Jan 13, 2025 |
| Albert Erani | 10% owner | 51,085,403 | 39.70% | Jan 13, 2025 |
| GN 2016 Family Trust u/a/d August 12, 2016 | 10% owner | 119,880,379 | 93.17% | Jan 13, 2025 |
| PFG LLC Organo | 10% owner | 68,594,976 | 53.31% | Jan 13, 2025 |
| Josette Ades | 10% owner | 102,170,804 | 79.40% | Jan 13, 2025 |
| RED Holdings, LLC | 10% owner | 59,223,027 | 46.03% | Jan 13, 2025 |
| Thompson Dean | 10% owner | 32,099,993 | 24.95% | Nov 19, 2024 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Michael Joseph Driscoll Director | Mar 9, 2026 | Buy | +10,000 | $2.67 | $26.70K | 225,707 |
| Arthur S. Leibowitz Director | Mar 9, 2026 | Buy | +5,000 | $2.68 | $13.40K | 291,014 |
| Robert Cavorsi Vice President, Strategy | Mar 1, 2026 | Tax withholding | −700 | $3.21 | $2.25K | 275,524 |
| Patrick Bilbo Chief Operating Officer | Feb 18, 2026 | Tax withholding | −16,375 | $3.84 | $62.88K | 1,128,312 |
| Patrick Bilbo Chief Operating Officer | Feb 18, 2026 | Award | +49,102 | – | – | 1,144,687 |
| David Francisco Chief Financial Officer | Feb 18, 2026 | Award | +44,040 | – | – | 745,999 |
| David Francisco Chief Financial Officer | Feb 18, 2026 | Tax withholding | −14,687 | $3.84 | $56.40K | 731,312 |
| Lori Freedman Chief Admin. and Legal Officer | Feb 18, 2026 | Tax withholding | −14,411 | $3.84 | $55.34K | 1,023,643 |
| Lori Freedman Chief Admin. and Legal Officer | Feb 18, 2026 | Award | +43,212 | – | – | 1,038,054 |
| Antonio S. Montecalvo Vice President, Health Policy | Feb 18, 2026 | Award | +11,330 | – | – | 230,016 |
| Antonio S. Montecalvo Vice President, Health Policy | Feb 18, 2026 | Tax withholding | −3,778 | $3.84 | $14.51K | 226,238 |
| Gary S. Gillheeney President and CEO, Director | Feb 18, 2026 | Award | +188,856 | – | – | 4,323,398 |
| Gary S. Gillheeney President and CEO, Director | Feb 18, 2026 | Tax withholding | −91,311 | $3.84 | $350.63K | 4,232,087 |
| Robert Cavorsi Vice President, Strategy | Feb 18, 2026 | Tax withholding | −5,487 | $3.84 | $21.07K | 276,224 |
| Robert Cavorsi Vice President, Strategy | Feb 18, 2026 | Award | +16,454 | – | – | 281,711 |
| Brian Grow Chief Commercial Officer | Feb 18, 2026 | Award | +48,818 | – | – | 911,611 |
| Brian Grow Chief Commercial Officer | Feb 18, 2026 | Tax withholding | −11,887 | $3.84 | $45.65K | 899,724 |
| Antonio S. Montecalvo Vice President, Health Policy | Feb 18, 2026 | Award | +11,218 | – | – | 229,904 |
| Antonio S. Montecalvo Vice President, Health Policy | Feb 18, 2026 | Tax withholding | −3,741 | $3.84 | $14.37K | 226,163 |
| Antonio S. Montecalvo Vice President, Health Policy | Feb 18, 2026 | Award | +40,625 | – | – | 218,686 |
| Prathyusha Duraibabu Director | Feb 18, 2026 | Award | +48,828 | – | – | 247,047 |
| Gary S. Gillheeney President and CEO, Director | Feb 18, 2026 | Award | +890,625 | – | – | 4,134,542 |
| Gary S. Gillheeney President and CEO, Director | Feb 18, 2026 | Award | +186,968 | – | – | 4,321,510 |
| Gary S. Gillheeney President and CEO, Director | Feb 18, 2026 | Tax withholding | −90,398 | $3.84 | $347.13K | 4,231,112 |
| Patrick Bilbo Chief Operating Officer | Feb 18, 2026 | Award | +210,937 | – | – | 1,095,585 |
| Patrick Bilbo Chief Operating Officer | Feb 18, 2026 | Award | +48,612 | – | – | 1,144,197 |
| Patrick Bilbo Chief Operating Officer | Feb 18, 2026 | Tax withholding | −16,212 | $3.84 | $62.25K | 1,127,985 |
| Garrett Lustig Director | Feb 18, 2026 | Award | +48,828 | – | – | 125,742 |
| Michael Joseph Driscoll Director | Feb 18, 2026 | Award | +48,828 | – | – | 215,707 |
| Jon L. Giacomin Director | Feb 18, 2026 | Award | +48,828 | – | – | 241,026 |
| Arthur S. Leibowitz Director | Feb 18, 2026 | Award | +48,828 | – | – | 286,014 |
| Gilberto Quintero Director | Feb 18, 2026 | Award | +48,828 | – | – | 239,073 |
| David Francisco Chief Financial Officer | Feb 18, 2026 | Award | +43,602 | – | – | 745,561 |
| David Francisco Chief Financial Officer | Feb 18, 2026 | Award | +195,312 | – | – | 701,959 |
| David Francisco Chief Financial Officer | Feb 18, 2026 | Tax withholding | −14,541 | $3.84 | $55.84K | 731,020 |
| Robert Cavorsi Vice President, Strategy | Feb 18, 2026 | Award | +93,750 | – | – | 265,257 |
| Robert Cavorsi Vice President, Strategy | Feb 18, 2026 | Tax withholding | −5,432 | $3.84 | $20.86K | 276,115 |
| Robert Cavorsi Vice President, Strategy | Feb 18, 2026 | Award | +16,290 | – | – | 281,547 |
| Brian Grow Chief Commercial Officer | Feb 18, 2026 | Award | +48,330 | – | – | 911,123 |
| Brian Grow Chief Commercial Officer | Feb 18, 2026 | Award | +234,375 | – | – | 862,793 |
| Brian Grow Chief Commercial Officer | Feb 18, 2026 | Tax withholding | −11,768 | $3.84 | $45.19K | 899,355 |
| Michele Ilene Korfin Director | Feb 18, 2026 | Award | +48,828 | – | – | 239,073 |
| Lori Freedman Chief Admin. and Legal Officer | Feb 18, 2026 | Award | +203,125 | – | – | 994,842 |
| Lori Freedman Chief Admin. and Legal Officer | Feb 18, 2026 | Tax withholding | −14,267 | $3.84 | $54.79K | 1,023,355 |
| Lori Freedman Chief Admin. and Legal Officer | Feb 18, 2026 | Award | +42,780 | – | – | 1,037,622 |
| Patrick Bilbo Chief Operating Officer | Feb 15, 2026 | Tax withholding | −28,331 | $3.73 | $105.67K | 915,617 |
| Patrick Bilbo Chief Operating Officer | Feb 15, 2026 | Tax withholding | −5,114 | $3.73 | $19.08K | 943,948 |
| Patrick Bilbo Chief Operating Officer | Feb 15, 2026 | Tax withholding | −15,617 | $3.73 | $58.25K | 900,000 |
| Patrick Bilbo Chief Operating Officer | Feb 15, 2026 | Tax withholding | −15,352 | $3.73 | $57.26K | 884,648 |
| Gary S. Gillheeney President and CEO, Director | Feb 15, 2026 | Tax withholding | −24,340 | $3.73 | $90.79K | 3,490,983 |
| Gary S. Gillheeney President and CEO, Director | Feb 15, 2026 | Tax withholding | −78,646 | $3.73 | $293.35K | 3,412,337 |
| Gary S. Gillheeney President and CEO, Director | Feb 15, 2026 | Tax withholding | −82,815 | $3.73 | $308.90K | 3,329,522 |
| Gary S. Gillheeney President and CEO, Director | Feb 15, 2026 | Tax withholding | −85,605 | $3.73 | $319.31K | 3,243,917 |
| Lori Freedman Chief Admin. and Legal Officer | Feb 15, 2026 | Tax withholding | −12,761 | $3.73 | $47.60K | 805,227 |
| Lori Freedman Chief Admin. and Legal Officer | Feb 15, 2026 | Tax withholding | −13,510 | $3.73 | $50.39K | 791,717 |
| Lori Freedman Chief Admin. and Legal Officer | Feb 15, 2026 | Tax withholding | −24,428 | $3.73 | $91.12K | 817,988 |
| Lori Freedman Chief Admin. and Legal Officer | Feb 15, 2026 | Tax withholding | −4,043 | $3.73 | $15.08K | 842,416 |
| Brian Grow Chief Commercial Officer | Feb 15, 2026 | Tax withholding | −11,144 | $3.73 | $41.57K | 628,418 |
| Brian Grow Chief Commercial Officer | Feb 15, 2026 | Tax withholding | −10,559 | $3.73 | $39.39K | 639,562 |
| Brian Grow Chief Commercial Officer | Feb 15, 2026 | Tax withholding | −3,346 | $3.73 | $12.48K | 669,031 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Organogenesis's stock actually held short. Settlement fails (shares not delivered on time) peaked at 85,841 shares on Sep 14, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Glenn H. Nussdorf Director, Stakeholder | Dec 16, 2025 | 200,000 | $1.02M | Dec 16, 2025 | Private Transaction |
| Glenn H. Nussdorf Director, Stakeholder | Nov 25, 2025 | 200,000 | $1.08M | Nov 25, 2025 | Private Transaction |
| Glenn H. Nussdorf Director, Stakeholder | Nov 24, 2025 | 100,000 | $534.38K | Nov 24, 2025 | Private Transaction |
| Michael Joseph Driscoll Director | Mar 17, 2025 | 25,000 | $127.00K | Mar 4, 2025 | Bonus |
| Gary S. Gillheeney Officer | Dec 6, 2024 | 380,000 | $1.36M | Dec 6, 2024 | Option Exercise |
| Albert Erani Part of a control group of shareholders | Jan 9, 2024 | 422,589 | $1.90M | Jan 9, 2024 | Original Issuance |
| RED Holdings, LLC Shareholder is part of a control group | Jan 9, 2024 | 2,000,000 | $8.98M | Jan 9, 2024 | Original issuance from debt conversion |
See a number that looks wrong?